The Cyclops for pulmonary delivery of aminoglycosides; A new member of the Twincer™ family

M. Hoppentocht*, O. W. Akkerman, P. Hagedoorn, H. W. Frijlink, A. H. de Boer

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

30 Citations (Scopus)

Abstract

Patients infected with pathogenic bacteria have to be treated with antibiotics. When the infection is in the lungs, as for instance in cystic fibrosis, bronchiectasis and tuberculosis, inhaled antibiotics have certain advantages over systemically administered antibiotics. In this study, it is shown that re-designing the Twincer™ high dose disposable inhaler into a device named Cyclops enables effective dispersion of up to 50 mg of pure spray dried tobramycin. This proves that spray dried tobramycin powders in the preferred size range for inhalation can be administered without applying complex particle engineering techniques and/or using excipients. Only some coarse sweeper crystals added separately are desired to minimise the inhaler losses to less than 20% at 4 kPa. The fine particle fractions
Original languageEnglish
Pages (from-to)8-15
Number of pages8
JournalEuropean Journal of Pharmaceutics and Biopharmaceutics
Volume90
DOIs
Publication statusPublished - Feb-2015

Keywords

  • Aminoglycosides
  • Antibiotics
  • Cystic fibrosis
  • Disposable inhaler
  • Dry powder dispersion
  • High drug dose
  • Tuberculosis
  • DRY POWDER INHALERS
  • CYSTIC-FIBROSIS
  • RESISTANT TUBERCULOSIS
  • PHASE-I
  • INHALATION
  • FORMULATION
  • PERFORMANCE
  • THERAPY

Cite this